Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

136.04 +0.47 (+0.35%)
Official Closing Price Updated: 7:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,845,224
Open 134.50
Bid (Size) 135.20 (1)
Ask (Size) 136.88 (1)
Prev. Close 135.57
Today's Range 134.22 - 136.69
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
The gold rush for obesity medications just got a bit more intense. 
Via The Motley Fool
Where Will Novo Nordisk Be in 10 Years?
Will Novo Nordisk top $1 trillion in market value? 
Via The Motley Fool

Performance

YTD
+33.23%
+33.23%
1 Month
+7.83%
+7.83%
3 Month
+10.20%
+10.20%
6 Month
+29.01%
+29.01%
1 Year
+67.40%
+67.40%

More News

Read More
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
Via Benzinga
Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression
Via Benzinga
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
Is Novo Nordisk Stock a Millionaire Maker?
Via The Motley Fool
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
Via InvestorPlace
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
Via Benzinga
Exposures Product Safety
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Via Benzinga
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Via InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Via Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Via Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Via InvestorPlace
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Via Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Via Benzinga
Magnificent Seven? Just Two Members Meet This Earnings Criteria
Via Investor's Business Daily
Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green
Via Investor's Business Daily
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.